Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines,?announced a change in control and leadership on February 26, 2025. Datuk Dr. Doris Wong Sing Ee?acquired the majority interest in Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) and will now serve as its Chief Executive Officer and Executive Director. Rimon attorneys?Debbie Klis?and?Marc C. Lee?led this deal advising Datuk Dr. Doris Wong Sing Ee, with support from counsel,?Olivia Y. Wang?and paralegal, Anne Mitzelfelt. We congratulate Cyclacel Pharmaceuticals, Inc. and Datuk Dr. Doris Wong Sing Ee on this exciting milestone! Read more here: https://lnkd.in/e-3zejTt #rimon #deals
